Medicover, a company with Swedish capital listed on the Stockholm exchange, presented its interim financial report for 2017. The company is active in Romania through its Medicover centres and Synevo laboratories, and had an increase of 16.7 percent in turnover in 2017, reaching EUR 580.2 million.
Fredrik Ragmark, Medicover CEO, said: “2017 was a prosperous year for the group, in which we finalised the listing process on Nasdaq Stockholm and continued to grow both organically and through acquisitions. Market conditions are stable and they support our development plans, especially in Poland and Romania.”
In 2017, the Medical Services division had a 16.8 growth in turnover, up to EUR 285.8 million. The Diagnostics Services division had an increase of 16.9 percent, reaching EUR 304.4 million.
On the Romanian market, the company’s turnover grew by 19.6 percent in 2017, up to EUR 73.8 million. Medicover Romania is in third place within the group, after Germany and Poland, with a share of 12.7 percent of turnover.
Adrian Peake, general manager of Medicover Romania: “In 2017 we continued to grow and fulfilled our objectives. Acquiring Iowemed, a top medical network in Constanta, was an important strategic step, together with our continuous investment into integrated medical services of the highest standard. The economic growth of the country and the workforce is reflected in the medical benefits offered by employers and supports people’s access to quality medical services.”
Laurentiu Luca, general manager of Synevo Romania: “The excellent results of the group make us confident that we are on the right track in Romania as well. Last year’s inauguration in Bucharest of the first Digital Histopathology Department in south-eastern Europe and the growing number of testing centres reaching a 75 percent territorial coverage are some of the factors that determined the growth of our local business and reconfirmed our position of leader in innovation.”